



VIA REGISTERED POST AND EMAIL

**Attention: Ji-won Cho, and Hunsuk Chung**

**DongBang Future Tech & Life Co., Ltd**

**78, Jeyakgongdan 4-gil, Hyangnam-Eup, Hwaseong-Si, 18622, Gyeonggi-Do,  
Korea**

**Email: [ra2@dongbangchem.co.kr](mailto:ra2@dongbangchem.co.kr); [hunsukchung@dongbangchem.co.kr](mailto:hunsukchung@dongbangchem.co.kr)**

Date: 29 August 2025

**Re: Mutual Termination Letter of Agreement to Terminate Molnupiravir Licence Agreement**

Dear Ji-won Cho,

dear Hunsuk Chung,

We refer to the licence agreement between the Medicines Patent Pool ("MPP") and DongBang Future Tech & Life Co., Ltd ("Licensee") dated 1/10/2022 concerning patents and know-how pertaining to molnupiravir ("Licence Agreement").

MPP and Licensee agree that the Licence Agreement is hereby terminated as of the date of last signature below. This termination is without prejudice to the surviving provisions of the Licence Agreement, including sections 3A, 6.1(e), 7.3, 8, 10.5, 11, and 12.

Please acknowledge your agreement to this termination letter by signing and returning a copy to us.

For and on behalf of **Medicines  
Patent Pool**

For and on behalf of **DongBang  
Future Tech & Life Co., Ltd**

A handwritten signature in black ink, appearing to be "CP", written over a horizontal line.

Name: Chan Park  
Title: General Counsel  
Date: 29 August 2025

A handwritten signature in black ink, appearing to be "Hunsuk", written over a horizontal line.

Name: Hunsuk Chung  
Title: President  
Date

03. September. 2025.